Greg M. Delgoffe
Showed as a graduate student in Jonathan Powell's lab that T cells lacking mTOR become regulatory rather than effector T cells, and that mTORC1 and mTORC2 steer different helper-T-cell fates
Professor of Immunology, Director of Tumor Microenvironment Center, UPMC Hillman Cancer Center; Editor-in-Chief, Immunology (Wiley) · postdoc, St. Jude (Dario Vignali lab) · PhD, Johns Hopkins (Jonathan D. Powell lab, 2010)
Delgoffe Lab, UPMC Hillman Cancer Center / University of Pittsburgh (Pittsburgh, Pennsylvania, USA) ↗ Bluesky@delgoffelab.bsky.social ↗ ORCID0000-0002-2957-8135 ↗
Portrait: UPMC Hillman Cancer Center / University of Pittsburgh
As a PhD student with Powell (who has his own profile in the Atlas), Delgoffe showed (DEL2009) that T cells lacking mTOR fail to differentiate into effector cells, defaulting toward Treg fate. He refined this (DEL2011): mTORC1 is required specifically for Th1/Th17 and mTORC2 for Th2 — which complex is active, not just mTOR on/off, dictates fate.
Built own program at Pitt around the idea that tumors selectively feed Tregs, not just starve killer T cells — tumor Tregs depend on taking up lactic acid through the transporter MCT1 (Nature 2021); dichloroacetate improves CAR-T persistence (Cell Metabolism 2025). Co-founded Novasenta and RemplirBio. CRI Lloyd J. Old STAR awardee.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2009 | M | The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment DEL2009 T cells lacking mTOR fail to differentiate into effector cells, defaulting toward Treg fate. |
| 2011 | A | The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2 DEL2011 mTORC1 and mTORC2 selectively program distinct CD4 helper T-cell lineages. |
| 2015 | A | mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation POL2015 Co-author: mTORC1 and mTORC2 steer CD8 T cells differently, with constant mTORC1 driving short-lived glycolytic effectors and loss of mTORC2 favouring long-lived memory cells (mice). |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Greg M. Delgoffe.
ShowHide
- Jonathan D. Powell 3 shared studies Showed that T cells lacking mTOR become regulatory T cells instead of effector cells, and that mTORC1 and mTORC2 each steer a different type of helper T cell
- Adam T. Waickman 2 shared studies Immunologist who trained in Jonathan Powell's mTOR and T cell lab at Johns Hopkins and now studies human immune responses to dengue virus at SUNY Upstate Medical University
- Kristen N. Pollizzi 2 shared studies Immunologist trained in Jonathan Powell's lab at Johns Hopkins who used gene deletions in mice to show how the two mTOR complexes push killer T cells toward effector or memory fates
- Maureen R. Horton Pulmonary physician-scientist who studies immune mechanisms of lung inflammation and fibrosis
- Sara C. Kozma Studies the S6K/mTOR pathway and how it controls cell growth, ribosome production, diabetes and cancer, including mTOR signalling in liver cancer.
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.